Loading patent…
AssigneeSumitomo Pharmaceuticals Company, Limited
InventorsMichiko Kishino, Chikao Nakayama, Mutsuo Taiji, Junji Ichihara, Hiroshi Noguchi
Estimating the term…
The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4/5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.
A method for controlling blood glucose levels in a mammal or patient having non-insulin dependent diabetes mellitus comprising:
A method for controlling blood lipid levels in a mammal or patient having non-insulin dependent diabetes mellitus comprising:
Dependencies are inferred from the claim text.